Family history and mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC).

To determine the influence of family medical history on mortality from cancer and other chronic diseases, participants in the JACC study were questioned about tuberculosis, apoplexy, hypertension, heart disease, diabetes mellitus and malignant diseases and followed up. Consistent across the sexes, a family history of tuberculosis was apparently linked to reduced risk of lung cancer, and also lowered ischemic heart disease. No consistent findings were obtained for hypertension, diabetes mellitus or cancer.

Personal past history and mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC).

To determine the influence of personal medical history on mortality from cancer and other chronic diseases, participants in the JACC study were questionned and followed up. Consistent across the sexes, risk of deaths of all causes was increased with hypertension, diabetes mellitus, apoplexy, liver diseases, surgical operations, and blood transfusions. All cancers were similarly related to a history of diabetes and liver diseases, surgery and transfusions. In addition, risk of liver cancer was elevated with diabetes, liver disease, cholecystectomy, renal disease, surgical operations and blood transfusions. Apoplexy was related to a past history of blood transfusion and diabetes, the latter also predisposing to ischemic heart disease. Links with infectious disease were also elucidated. Clearly, a past medical history can exert a strong influence on chronic disease development.

Lack of an association between serum level of transforming growth factor beta -1 and stomach cancer risk in the JACC study.

Alterations in the serum concentration of transforming growth factor beta-1 (TGFbeta1) have been observed in gastric cancer patients. No study, however, has ever examined the association between the serum TGFbeta1 level and stomach cancer prospectively. We conducted a prospective, nested case-control analysis among apparently healthy men and women who were followed for up to 8 years in the JACC Study to assess whether serum level of total TGFbeta1 is associated with a subsequent risk of stomach cancer. The concentration of serum TGFbeta1 in previously collected blood samples was analyzed by ELISA for 209 individuals in whom a diagnosis of stomach cancer was documented, and for 409 controls matched with them for gender, age and study area. Baseline blood levels of TGFbeta1 were not related to the risk of stomach cancer in either men or women, a finding unchanged even after adjustment for potential confounders. The multivariate-adjusted odds ratio of stomach cancer in men and women was 1.10 (95% CI, 0.82 to 1.48) and 1.09 (95% CI, 0.80 to 1.48), respectively, for each increase of 1 SD in the TGFbeta1 value. In conclusion, serum TGFbeta1 levels were not associated with increased risks of subsequent stomach cancer.gene A52C polymorphism related to the metabolism of long-chain fatty acids and oxidized LDL in the etiology of colorectal cancer.